New Drug Reports in NFLIS-Drug: The following drugs were reported to NFLIS-Drug for the first time between July 1, 2019, and September 30, 2019, and were submitted to a NFLIS participating laboratory on or after July 1, 2018.

### Snapshot of Drug Reports Received by NFLIS-Drug

The tables on the right present drug reports received by NFLIS-Drug between July 1, 2019, and September 30, 2019, that were submitted to a NFLIS participating laboratory on or after July 1, 2018.

1. BMDP = 3,4-methylenedioxyn-benzylcathinone.
2. Includes all positional and nonspecified isomers as reported by participating laboratories.
3. Does not include benzodiazepines.
4. Does not include reports of fentanyl.

### Upward Trends

#### Eutylone

- **Percent of All Drug Reports**
  - **SEP ’17**: 0.2
  - **AUG ’19**: 0.5

#### Etizolam

- **Percent of All Drug Reports**
  - **SEP ’17**: 0.05
  - **AUG ’19**: 0.2

#### Benzphetamine

- **Percent of All Drug Reports**
  - **SEP ’17**: 0.0
  - **AUG ’19**: 0.5

### Data Disclaimer:

Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS database in October 2019 and include drug reports received by NFLIS-Drug through the end of September 2019. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/2k17NFLISQA.pdf. NFLIS reports are available at https://www.nflis.deadiversion.usdoj.gov/Reports.aspx. Questions and comments: DEANFLIS@rti.org